Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations.
Villaruz LC, Wang X, Bertino EM, Gu L, Antonia SJ, Burns TF, Clarke J, Crawford J, Evans TL, Friedland DM, Otterson GA, Ready NE, Wozniak AJ, Stinchcombe TE. Villaruz LC, et al. Among authors: ready ne. ESMO Open. 2023 Apr;8(2):101183. doi: 10.1016/j.esmoop.2023.101183. Epub 2023 Mar 9. ESMO Open. 2023. PMID: 36905787 Free PMC article. Clinical Trial.
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
Ready NE, Audigier-Valette C, Goldman JW, Felip E, Ciuleanu TE, Rosario García Campelo M, Jao K, Barlesi F, Bordenave S, Rijavec E, Urban L, Aucoin JS, Zannori C, Vermaelen K, Arén Frontera O, Curioni Fontecedro A, Sánchez-Gastaldo A, Juan-Vidal O, Linardou H, Poddubskaya E, Spigel DR, Ahmed S, Maio M, Li S, Chang H, Fiore J, Acevedo A, Paz-Ares L. Ready NE, et al. J Immunother Cancer. 2023 Feb;11(2):e006127. doi: 10.1136/jitc-2022-006127. J Immunother Cancer. 2023. PMID: 36725084 Free PMC article. Clinical Trial.
Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study.
Bodd MH, Locke SC, Wolf SP, Antonia S, Crawford J, Hartman J, Herring KW, Ready NE, Stinchcombe TE, Troy JD, Williams C, Clarke JM, LeBlanc TW. Bodd MH, et al. Among authors: ready ne. Lung Cancer. 2023 Jan;175:17-26. doi: 10.1016/j.lungcan.2022.11.010. Epub 2022 Nov 21. Lung Cancer. 2023. PMID: 36442383
A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial.
Clarke JM, Gu L, Wang XF, Stinchcombe TE, Stevenson MM, Ramalingam S, Shariff A, Garst J, Nixon AB, Antonia SJ, Crawford J, Ready NE. Clarke JM, et al. Among authors: ready ne. JTO Clin Res Rep. 2022 May 17;3(6):100337. doi: 10.1016/j.jtocrr.2022.100337. eCollection 2022 Jun. JTO Clin Res Rep. 2022. PMID: 35719867 Free PMC article.
51 results